ADVB
Advanced Biomed, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$2.30
−12.88%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- +522.0%
- Free cash flow
- +72.0%
- Operating cash flow
- +72.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- +304.9%
- EPS
- +3431.3%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026